Dell Technologies Inc vs Nuwellis Inc — how do they compare? Dell Technologies Inc trades at $586.28 (market cap $365.31B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Dell Technologies Inc is far larger — about 166050× Nuwellis Inc's market cap, and Dell Technologies Inc pays a 0.44% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Nuwellis Inc for 26 Days on average.
| DELL | NUWE | |
|---|---|---|
Market Cap | $365.31B | $2.20M |
Volume | 5,121,365 | 121,544 |
Sector | Technology | Health |
52-Week High | $588.67 | $146.65 |
52-Week Low | $111.10 | $0.68 |
Typical Hold Time | 57 Days | 26 Days |
Enterprise Value | $388.20B | -$1.52M |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $574.74, down 0.73% on the day, with a bullish technical signal and strong fundamental momentum. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $7.04 surpassing expectations by 43%. The company's AI server business is a key growth driver, with a backlog surging to $95 billion and fiscal 2027 revenue guidance raised to approximately $192 billion. Positive analyst sentiment is reflected in a 55.56% buy rating, though the stock trades above the consensus price target of $566.35.
The outlook for Dell is optimistic, driven by explosive AI server demand and robust financial performance. Investment opportunities include continued revenue growth and margin expansion, supported by a capital-light model. Risks include execution challenges in meeting high demand, competitive pressures, and market volatility. The stock's current valuation at a P/E of 33.42 may limit near-term upside if growth moderates.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →